Litigation Details for Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Docket		Date Filed	2017-06-26
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	Defendant	Referred To
Patents	6,509,376; 7,320,999; 7,619,001; 8,399,514; 8,759,393
Link to Docket	External link to docket

Details for Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-06-26	236	Opinion - Memorandum Opinion	alleging infringement of U.S. Patent Nos. 6,509,376 ("the ' 376 patent"), 7,320,999 ("the… 514 patent") (collectively, "patents-in-suit" or "asserted patents"). …;the ' 999 patent"), 7,619,001 ("the ' 001 patent"), 7,803 ,840 ("the '…#39; 840 patent"), 8,759,393 ("the ' 393 patent"), and 8,399,514 ("the ' 514…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the	External link to document

Biogen International GmbH v. Amneal Pharmaceuticals LLC: Tecfidera Patent Litigation Summary

Last updated: September 25, 2026

Biogen International GmbH sued Amneal Pharmaceuticals LLC in the District of Delaware over Amneal’s abbreviated new drug application for generic dimethyl fumarate, the active ingredient in Tecfidera. The dispute centered on U.S. Patent No. 6,509,376, which claimed methods for treating multiple sclerosis with dimethyl fumarate and related fumarate compounds.

The patent was later held invalid for lack of written description in parallel litigation involving Mylan. The Federal Circuit affirmed that ruling. The decision removed the principal patent barrier to generic Tecfidera entry and materially reduced Biogen’s ability to delay ANDA approvals through the same patent estate.

What was Biogen International GmbH v. Amneal about?

Biogen’s complaint alleged that Amneal’s proposed generic dimethyl fumarate product would infringe the ’376 patent under the Hatch-Waxman Act. The case was filed in the U.S. District Court for the District of Delaware under Case No. 1:17-cv-00823-LPS.

Item	Detail
Plaintiff	Biogen International GmbH
Defendant	Amneal Pharmaceuticals LLC
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-00823-LPS
Judge	Leonard P. Stark
Product	Tecfidera, delayed-release dimethyl fumarate capsules
Regulatory vehicle	Abbreviated New Drug Application
Principal patent	U.S. Patent No. 6,509,376
Technology	Oral fumarate treatment for multiple sclerosis
Litigation type	Hatch-Waxman patent infringement action
Main commercial issue	Timing of generic dimethyl fumarate entry

The litigation was part of a broader group of Biogen cases against generic manufacturers that filed Paragraph IV certifications concerning the Tecfidera patent.

What patent protected Tecfidera in the Amneal case?

The central patent was U.S. Patent No. 6,509,376, titled “Treatment for Multiple Sclerosis.” The patent was originally associated with Fumapharm AG and later held by Biogen International GmbH.

The disputed claims covered methods of treating multiple sclerosis by administering therapeutically effective amounts of dimethyl fumarate, monomethyl fumarate, or combinations of those compounds. The litigation focused on whether the patent specification adequately described the narrower claimed treatment involving dimethyl fumarate.

The key legal issue was not whether fumarate compounds appeared somewhere in the specification. It was whether the specification demonstrated possession of the specific claimed method at the relevant filing date.

Patent profile

Patent	Subject matter	Listed owner or assignee	Relevant term
U.S. 6,509,376	Treatment of multiple sclerosis with fumarate compounds	Biogen International GmbH	Expired in 2020

The ’376 patent was the principal Orange Book patent associated with Tecfidera’s multiple sclerosis indication. The litigation did not principally concern a separate formulation patent covering the capsule shell, excipients, or a manufacturing process.

When did the Tecfidera patent expire?

The ’376 patent expired in 2020. The expiration date was a major factor in the commercial value of the case because any injunction or 30-month stay could not extend beyond the patent term.

Tecfidera received FDA approval on March 27, 2013, under NDA No. 204063. Its five-year new chemical entity exclusivity ended in March 2018. Patent protection, rather than FDA regulatory exclusivity, remained the main barrier to generic entry after that date.

Milestone	Date or period
Tecfidera FDA approval	March 27, 2013
NCE exclusivity expiration	March 27, 2018
’376 patent expiration	2020
Federal Circuit affirmance of invalidity in parallel litigation	2021

The patent’s expiration reduced the economic value of continued litigation, but the invalidity ruling remained important because it eliminated the patent as a basis for blocking generic approvals and supported generic entry against other defendants.

What was the Paragraph IV challenge?

Amneal’s ANDA included a Paragraph IV certification asserting that the relevant Biogen patent was invalid, unenforceable, or would not be infringed by Amneal’s proposed product.

Biogen’s lawsuit triggered the Hatch-Waxman 30-month stay of FDA approval, subject to the statutory conditions governing the filing of an infringement action after receipt of a Paragraph IV notice. The commercial purpose of the litigation was to preserve Tecfidera’s market exclusivity while the patent dispute proceeded.

Paragraph IV litigation required Biogen to prove infringement and defend the validity of the ’376 patent. Amneal did not need to prove that its product was clinically equivalent to Tecfidera in the district court. FDA approval of the ANDA remained a separate regulatory process.

How did the invalidity ruling affect the Amneal case?

The decisive development came from parallel litigation against Mylan. In that case, the District of Delaware held the asserted ’376 claims invalid for lack of written description. The Federal Circuit affirmed the judgment in Biogen International GmbH v. Mylan Pharmaceuticals Inc., 18 F.4th 1333 (Fed. Cir. 2021).

The Federal Circuit agreed that the specification did not adequately describe the claimed method of treating multiple sclerosis with dimethyl fumarate. The court rejected the argument that a broad disclosure of fumarate compounds and treatment concepts sufficiently supported the specific claims directed to dimethyl fumarate treatment.

Core holding

The specification disclosed a broad genus and related subject matter, but the asserted claims required a particular species and treatment method. The written-description requirement demanded more than a research direction or a list of possible compounds. The disclosure had to demonstrate possession of the claimed subject matter.

The ruling was significant for the Amneal case because the same patent and substantially overlapping validity issues were involved in the coordinated Tecfidera litigation. Once the ’376 patent was held invalid and that result was affirmed, Biogen could no longer rely on the patent to prevent generic approval or launch.

Was the ’376 patent found infringed?

The principal adjudicated issue in the parallel Mylan case was validity. The district court’s finding that the claims were invalid eliminated the practical need for an injunction based on infringement.

For the Amneal matter, the commercial result was that Biogen did not retain an enforceable patent barrier capable of excluding Amneal’s generic product through the expiration date. The invalidity determination was more important than a final infringement judgment because an invalid patent cannot support injunctive relief or damages for infringement.

What was the litigation status of the Amneal case?

The Amneal action was one of several Delaware Tecfidera cases filed against ANDA applicants. The publicly reported outcome must be evaluated together with the invalidity rulings in the related Biogen cases.

The case did not produce a durable patent victory for Biogen. The ’376 patent was ultimately invalidated in parallel proceedings, and the Federal Circuit affirmed the invalidity judgment. That result eliminated the central legal basis for continued exclusion of Amneal and other generic applicants.

The public litigation record does not establish a commercially significant settlement that preserved long-term market exclusivity for Biogen. The case’s practical resolution was driven by the invalidity of the asserted patent and the patent’s 2020 expiration.

Did the case involve a formulation patent?

The Amneal dispute was principally a method-of-use patent case, not a formulation patent case.

Tecfidera is an oral delayed-release capsule. Formulation-related protection can be commercially important for solid oral products because patents may cover enteric coatings, dosage forms, particle sizes, excipients, release profiles, or manufacturing processes. The reported Amneal case, however, centered on the ’376 patent’s method claims concerning treatment of multiple sclerosis with fumarate compounds.

Protection category	Relevance to Amneal case
Method of treatment	Central issue
Active ingredient	Dimethyl fumarate
Delayed-release formulation	Product characteristic, not the principal litigated patent
Manufacturing process	Not the principal asserted basis reported in the case
Device or delivery system	Not central
Biologic patent	Not applicable

This distinction matters because invalidation of the ’376 method patent did not automatically invalidate every possible patent that might have covered a Tecfidera formulation or manufacturing process. It removed the principal patent identified with the case and the main barrier to generic dimethyl fumarate entry.

What was the FDA and Orange Book status of Tecfidera?

Tecfidera was approved as a small-molecule drug under the conventional NDA pathway. Generic applicants used the ANDA pathway and were required to demonstrate pharmaceutical equivalence and bioequivalence to the reference product.

The Orange Book listed the ’376 patent for Tecfidera. The listed patent was the subject of Paragraph IV certifications and subsequent litigation against multiple ANDA applicants.

Regulatory issue	Status
Reference product	Tecfidera
Active ingredient	Dimethyl fumarate
FDA application	NDA 204063
Generic pathway	ANDA
FDA exclusivity	Five-year NCE exclusivity ended in 2018
Patent listing	U.S. Patent No. 6,509,376
Biosimilar pathway	Not applicable

Because dimethyl fumarate is a small molecule, the relevant competitive pathway was generic substitution rather than biosimilar interchangeability under the Public Health Service Act.

Which companies challenged Biogen’s Tecfidera patent?

Biogen faced multiple ANDA challenges to the ’376 patent. Publicly reported litigation included actions involving Mylan, Amneal, Zydus and other generic applicants.

The coordinated cases created a common validity risk. A final ruling invalidating the patent in one case could materially affect Biogen’s ability to maintain the same patent against other applicants, particularly where the same claims and written-description arguments were presented.

The competitive significance was greater than the individual Amneal case because the same ruling affected the legal position of the broader generic field.

What generic entry risks did Biogen face?

Biogen faced four principal risks:

1. Invalidity of the only meaningful Orange Book patent.
2. FDA approval of multiple ANDAs after the 30-month stay or patent expiration.
3. Rapid price erosion from several generic suppliers.
4. Loss of the ability to negotiate delayed-entry settlements supported by a strong patent position.

The invalidity ruling converted the market from a patent-controlled launch environment to a generic-entry environment. Multiple approved or launch-ready ANDAs could accelerate substitution and reduce net sales more quickly than a single generic entrant.

Generic launch scenarios

Scenario	Commercial effect
Single generic entrant	Moderate initial price erosion
Several simultaneous entrants	Faster loss of branded volume and price
Authorized generic or licensing arrangement	Potentially slower erosion, depending on supply terms
Patent-based injunction	Removed after invalidity ruling
Post-expiration entry	Available once regulatory requirements were met

The case did not involve biosimilar competition. Generic dimethyl fumarate products could compete through ANDA approval and pharmacy substitution rules applicable to small-molecule products.

How strong was Biogen’s Tecfidera patent estate?

The estate was commercially valuable but legally vulnerable. The ’376 patent had broad commercial reach because it covered the therapeutic use of dimethyl fumarate in multiple sclerosis. Its weakness was the written-description gap identified by the district court and Federal Circuit.

Strength factor	Assessment
Market relevance	High
Remaining term when litigation began	Limited
Claim breadth	Commercially broad
Written-description support	Ultimately inadequate
Formulation protection in this case	Limited or not central
Ability to block generic entry	Eliminated by invalidity ruling
Litigation leverage after 2020 expiration	Low

The case illustrates the risk of relying on a broad method claim when the specification does not adequately support the specific active ingredient and treatment method later selected for commercialization.

What was the revenue exposure for Biogen?

Tecfidera was one of Biogen’s largest commercial products. Biogen reported approximately $4.4 billion in Tecfidera revenue in 2019 and approximately $4.2 billion in 2020, before the full impact of generic competition was reflected across later periods (Biogen, 2021).

The Amneal litigation therefore involved material revenue exposure. The risk was not limited to damages from one ANDA applicant. Loss of the ’376 patent affected the entire generic competitive landscape for dimethyl fumarate.

Revenue exposure was concentrated in:

• U.S. Tecfidera sales.
• Multiple sclerosis prescriptions subject to substitution.
• The period between patent invalidation, patent expiration and broad generic availability.
• The speed at which pharmacies and payers moved patients to generic dimethyl fumarate.

Tecfidera sales declined sharply after generic entry and the removal of the principal patent barrier. Other Biogen multiple sclerosis products, including Vumerity, became more important to the company’s franchise strategy, but Vumerity had a different active ingredient and formulation profile.

What does the case mean for patent litigation strategy?

The case has four practical implications for pharmaceutical companies and ANDA filers.

First, method-of-use claims must be supported by a specification that describes the specific clinical method and active ingredient, not merely a broad genus of possible compounds.

Second, coordinated litigation against multiple ANDA applicants can create significant collateral risk. A validity loss in one case can weaken or eliminate the patent holder’s position across related cases.

Third, a patent’s remaining term affects litigation economics. When the patent is close to expiration, a Paragraph IV challenge can create leverage even if the patent holder wins only limited interim relief.

Fourth, small-molecule products require separate analysis of method, formulation, process and dosage-form patents. Defeat of one patent does not automatically resolve every patent risk, but it can remove the primary commercial barrier.

Key Takeaways

• Biogen sued Amneal over an ANDA for generic dimethyl fumarate, the active ingredient in Tecfidera.
• The case centered on U.S. Patent No. 6,509,376.
• The patent claimed methods of treating multiple sclerosis with fumarate compounds.
• The patent was held invalid for lack of written description in parallel Mylan litigation.
• The Federal Circuit affirmed the invalidity ruling in 2021.
• The patent expired in 2020, eliminating any continuing exclusionary right.
• The dispute involved generic competition, not biosimilar competition.
• The case materially increased the risk of rapid Tecfidera revenue erosion.
• The principal legal weakness was inadequate written-description support for the specific dimethyl fumarate treatment claims.
• The public record does not show a durable settlement preserving Biogen’s patent-based market exclusivity.

FAQs

Was Amneal allowed to market generic Tecfidera?

The invalidity of the ’376 patent removed the primary patent barrier to Amneal’s generic dimethyl fumarate product. Actual marketing also depended on FDA approval and Amneal’s commercial launch decisions.

Did Biogen’s Tecfidera patent cover the dimethyl fumarate molecule itself?

The principal patent in the case covered methods of treating multiple sclerosis using fumarate compounds. It was not a basic composition-of-matter patent claiming dimethyl fumarate in all uses.

Did the Amneal case concern Vumerity?

No. The case concerned Tecfidera and generic dimethyl fumarate. Vumerity contains diroximel fumarate and is a different product.

Could Biogen rely on a formulation patent after the ’376 patent was invalidated?

Potentially, if a separate enforceable formulation or manufacturing patent covered the generic product. The Amneal case itself centered on the ’376 method patent, and its invalidity removed the principal patent at issue.

Was the Tecfidera competition governed by biosimilar law?

No. Dimethyl fumarate is a small-molecule active ingredient. Generic competition proceeded through the ANDA and Hatch-Waxman framework rather than the biosimilar pathway.

References

1. Biogen International GmbH v. Amneal Pharmaceuticals LLC, No. 1:17-cv-00823-LPS, U.S. District Court for the District of Delaware.

2. Biogen International GmbH v. Mylan Pharmaceuticals Inc., 18 F.4th 1333 (Fed. Cir. 2021).

3. Biogen International GmbH v. Mylan Pharmaceuticals Inc., U.S. District Court for the District of Delaware, No. 1:17-cv-01082-LPS.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

5. U.S. Food and Drug Administration. (2013). Tecfidera prescribing information, NDA No. 204063. FDA.

6. Biogen Inc. (2021). 2020 annual report. Biogen Inc.